These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 12649129)

  • 1. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.
    Delaunay J; Vey N; Leblanc T; Fenaux P; Rigal-Huguet F; Witz F; Lamy T; Auvrignon A; Blaise D; Pigneux A; Mugneret F; Bastard C; Dastugue N; Van den Akker J; Fière D; Reiffers J; Castaigne S; Leverger G; Harousseau JL; Dombret H; ; ; ; ;
    Blood; 2003 Jul; 102(2):462-9. PubMed ID: 12649129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
    Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
    Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
    Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
    Byrd JC; Mrózek K; Dodge RK; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Patil SR; Rao KW; Watson MS; Koduru PR; Moore JO; Stone RM; Mayer RJ; Feldman EJ; Davey FR; Schiffer CA; Larson RA; Bloomfield CD;
    Blood; 2002 Dec; 100(13):4325-36. PubMed ID: 12393746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.
    Buonamici S; Ottaviani E; Testoni N; Montefusco V; Visani G; Bonifazi F; Amabile M; Terragna C; Ruggeri D; Piccaluga PP; Isidori A; Malagola M; Baccarani M; Tura S; Martinelli G
    Blood; 2002 Jan; 99(2):443-9. PubMed ID: 11781223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.
    Nguyen S; Leblanc T; Fenaux P; Witz F; Blaise D; Pigneux A; Thomas X; Rigal-Huguet F; Lioure B; Auvrignon A; Fière D; Reiffers J; Castaigne S; Leverger G; Harousseau JL; Socié G; Dombret H
    Blood; 2002 May; 99(10):3517-23. PubMed ID: 11986202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
    Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
    Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
    Eghtedar A; Borthakur G; Ravandi F; Jabbour E; Cortes J; Pierce S; Kantarjian H; Garcia-Manero G
    Am J Hematol; 2012 Mar; 87(3):317-8. PubMed ID: 22228403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.
    Chang M; Raimondi SC; Ravindranath Y; Carroll AJ; Camitta B; Gresik MV; Steuber CP; Weinstein H
    Leukemia; 2000 Jul; 14(7):1201-7. PubMed ID: 10914543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults.
    Min GJ; Kim HJ; Yoon JH; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1621-1628. PubMed ID: 29698793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
    Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
    Mandelli F; Vignetti M; Suciu S; Stasi R; Petti MC; Meloni G; Muus P; Marmont F; Marie JP; Labar B; Thomas X; Di Raimondo F; Willemze R; Liso V; Ferrara F; Baila L; Fazi P; Zittoun R; Amadori S; de Witte T
    J Clin Oncol; 2009 Nov; 27(32):5397-403. PubMed ID: 19826132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
    Tavernier E; Le QH; Elhamri M; Thomas X
    Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.
    Haferlach T; Gassmann W; Löffler H; Jürgensen C; Noak J; Ludwig WD; Thiel E; Haase D; Fonatsch C; Becher R
    Ann Hematol; 1993 Apr; 66(4):165-70. PubMed ID: 8485203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.